Study: Monsanto’s Roundup Herbicide Probably Causes Cancer [UPDATED]

<a href="http://www.shutterstock.com/cat.mhtml?lang=en&language=en&ref_site=photo&search_source=search_form&version=llv1&anyorall=all&safesearch=1&use_local_boost=1&searchterm=herbicides&show_color_wheel=1&orient=&commercial_ok=&media_type=images&search_cat=&searchtermx=&photographer_name=&people_gender=&people_age=&people_ethnicity=&people_number=&color=&page=1&inline=258516386">keantian</a>/Shutterstock

Fight disinformation: Sign up for the free Mother Jones Daily newsletter and follow the news that matters.


UPDATE: Monsanto is trying furiously to discredit the World Health Organization’s assessment that glyphosate is a probable carcinogen. The company is pushing the WHO to retract the assessment, Reuters reports. And in an email, a Monsanto public relations person wrote that “[W]e are reaching out to the World Health Organization (WHO) to understand how, despite the wealth of existing science on glyphosate, the IARC [International Agency for Research on Cancer] panel could make a classification that disagrees with scientific and regulatory reviews.”

Monsanto has assured the public over and over that its flagship Roundup herbicide doesn’t cause cancer. In a stunning assessment (free registration required) published in The Lancet, a working group of scientists convened by the World Health Organization reviewed the recent research on glyphosate, the key ingredient in Roundup and the globe’s most widely used weed-killing chemical, and found it “probably carcinogenic to humans.”

One scientist called the report’s finding “the most surprising thing I’ve heard in 30 years” of studying agriculture.

The authors cited three studies that suggest occupational glyphosate exposure (e.g., for farm workers) causes “increased risks for non-Hodgkin lymphoma that persisted after adjustment for other pesticides.” They also point to both animal and human studies suggesting that the chemical, both in isolation and in the mix used in the fields by farmers, “induced DNA and chromosomal damage in mammals, and in human and animal cells in vitro”; and another one finding “increases in blood markers of chromosomal damage” in residents of several farm communities after spraying of glyphosate formulations.

Monsanto first rolled out glyphosate herbicides in 1974, and by the mid-1990s began rolling out corn, soy, and cotton seeds genetically altered to resist it. Last year, herbicide-tolerant crops accounted for 94 percent of soybeans and 89 percent of corn, two crops that cover more than half of US farmland. The rise of so-called Roundup Ready crops has led to a spike in glyphosate use, a 2012 paper by Washington State University researcher Charles Benbrook showed.

Benbrook told me the WHO’s assessment is “the most surprising thing I’ve heard in 30 years” of studying agriculture. Though a critic of the agrichemical industry, Benbrook has long seen glyphosate as a “relatively benign” herbicide. The WHO report challenges that widely held view, he said. “I had thought WHO might find it to be a ‘possible’ carcinogen,” Benbrook said. “‘Probable,’ I did not expect.”

He added that the report delivered no specific conclusions about the dosage glyphosate requires to trigger cancer. But given that US Geological Survey researchers have found it in detectable levels in air, rain, and streams in heavy-usage regions, that it’s widely used in parks, that it has also been found in food residues (though the US Department of Agriculture does not regularly test for it), the Environmental Protection Agency will likely come under heavy pressure to demand new research on it. Most US research on glyphosate, Benbrook added, has focused on the chemical in isolation. But in the real world, glyphosate is mixed with other chemicals, called surfactants and adjuvants, that enhance their weed-slaying power. Importantly, some of the research used in the WHO assessment came from outside the US and looked at real-world herbicide formulations.

Monsanto shares closed nearly 2 percent lower Monday as investors digested the news. It’s not heard to see why they’re squeamish. The agribusiness giant is most known for its high-tech seeds, but its old-line herbicide business remains quite the cash cow, as its 2014 annual report shows. That year, the division reaped about a third of the company’s $15.8 billion in total sales. Indeed, Monsanto’s herbicide sales grew at a robust 13 percent in 2014 clip, vs. an anemic 4 percent for its other division, seeds and genomics.

WE'LL BE BLUNT

It is astonishingly hard keeping a newsroom afloat these days, and we need to raise $253,000 in online donations quickly, by October 7.

The short of it: Last year, we had to cut $1 million from our budget so we could have any chance of breaking even by the time our fiscal year ended in June. And despite a huge rally from so many of you leading up to the deadline, we still came up a bit short on the whole. We can’t let that happen again. We have no wiggle room to begin with, and now we have a hole to dig out of.

Readers also told us to just give it to you straight when we need to ask for your support, and seeing how matter-of-factly explaining our inner workings, our challenges and finances, can bring more of you in has been a real silver lining. So our online membership lead, Brian, lays it all out for you in his personal, insider account (that literally puts his skin in the game!) of how urgent things are right now.

The upshot: Being able to rally $253,000 in donations over these next few weeks is vitally important simply because it is the number that keeps us right on track, helping make sure we don't end up with a bigger gap than can be filled again, helping us avoid any significant (and knowable) cash-flow crunches for now. We used to be more nonchalant about coming up short this time of year, thinking we can make it by the time June rolls around. Not anymore.

Because the in-depth journalism on underreported beats and unique perspectives on the daily news you turn to Mother Jones for is only possible because readers fund us. Corporations and powerful people with deep pockets will never sustain the type of journalism we exist to do. The only investors who won’t let independent, investigative journalism down are the people who actually care about its future—you.

And we need readers to show up for us big time—again.

Getting just 10 percent of the people who care enough about our work to be reading this blurb to part with a few bucks would be utterly transformative for us, and that's very much what we need to keep charging hard in this financially uncertain, high-stakes year.

If you can right now, please support the journalism you get from Mother Jones with a donation at whatever amount works for you. And please do it now, before you move on to whatever you're about to do next and think maybe you'll get to it later, because every gift matters and we really need to see a strong response if we're going to raise the $253,000 we need in less than three weeks.

payment methods

WE'LL BE BLUNT

It is astonishingly hard keeping a newsroom afloat these days, and we need to raise $253,000 in online donations quickly, by October 7.

The short of it: Last year, we had to cut $1 million from our budget so we could have any chance of breaking even by the time our fiscal year ended in June. And despite a huge rally from so many of you leading up to the deadline, we still came up a bit short on the whole. We can’t let that happen again. We have no wiggle room to begin with, and now we have a hole to dig out of.

Readers also told us to just give it to you straight when we need to ask for your support, and seeing how matter-of-factly explaining our inner workings, our challenges and finances, can bring more of you in has been a real silver lining. So our online membership lead, Brian, lays it all out for you in his personal, insider account (that literally puts his skin in the game!) of how urgent things are right now.

The upshot: Being able to rally $253,000 in donations over these next few weeks is vitally important simply because it is the number that keeps us right on track, helping make sure we don't end up with a bigger gap than can be filled again, helping us avoid any significant (and knowable) cash-flow crunches for now. We used to be more nonchalant about coming up short this time of year, thinking we can make it by the time June rolls around. Not anymore.

Because the in-depth journalism on underreported beats and unique perspectives on the daily news you turn to Mother Jones for is only possible because readers fund us. Corporations and powerful people with deep pockets will never sustain the type of journalism we exist to do. The only investors who won’t let independent, investigative journalism down are the people who actually care about its future—you.

And we need readers to show up for us big time—again.

Getting just 10 percent of the people who care enough about our work to be reading this blurb to part with a few bucks would be utterly transformative for us, and that's very much what we need to keep charging hard in this financially uncertain, high-stakes year.

If you can right now, please support the journalism you get from Mother Jones with a donation at whatever amount works for you. And please do it now, before you move on to whatever you're about to do next and think maybe you'll get to it later, because every gift matters and we really need to see a strong response if we're going to raise the $253,000 we need in less than three weeks.

payment methods

We Recommend

Latest

Sign up for our free newsletter

Subscribe to the Mother Jones Daily to have our top stories delivered directly to your inbox.

Get our award-winning magazine

Save big on a full year of investigations, ideas, and insights.

Subscribe

Support our journalism

Help Mother Jones' reporters dig deep with a tax-deductible donation.

Donate